[Skip to Content]
[Skip to Content Landing]
Article
November 1989

Treatment of Systemic Fungal Infections With Liposomal Amphotericin B

Author Affiliations

From the Section of Immunobiology and Drug Carriers, Division of Medicine (Drs Lopez-Berestein and Mehta), the Departments of Hematology (Dr Keating) and Pediatrics (Dr Frankel), and the Section of Infectious Diseases, Division of Medicine, Department of Internal Medicine (Drs Bodey and Fainstein), The University of Texas M. D. Anderson Cancer Center, and the Department of Infectious Diseases, St Luke's Hospital (Drs Zeluff and Gentry), Houston, Tex.

Arch Intern Med. 1989;149(11):2533-2536. doi:10.1001/archinte.1989.00390110097022
Abstract

• Forty-six patients with systemic fungal infections were treated with liposomal amphotericin B. Twenty-one patients had disseminated candidiasis, 19 had aspergillosis, and the rest had a variety of other fungal infections. Forty patients failed to respond to conventional amphotericin B therapy, and 6 patients were given liposomal amphotericin B because conventional amphotericin B caused severe side effects. Twenty-four patients had a complete response, and 22 patients failed to respond. No short- or long-term toxic reactions were observed. The acute side effects such as fever, chills, and potassium loss were infrequent and milder than those commonly observed with conventional amphotericin B. No chronic renal, hematologic, or central nervous system side effects were observed. Liposomal amphotericin B therapy was effective and less toxic than conventional amphotericin B therapy.

(Arch Intern Med. 1989;149:2533-2536)

×